Atlas Trials

Recurrent Bladder Urothelial Carcinoma

8 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Recurrent Bladder Urothelial Carcinoma

RecordFirmDate
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy (NCT04963153)National Cancer Institute (NCI)2022-07-07
ARID1A and/or KDM6A Mutation and CXCL13 Expression (NCT04953104)M.D. Anderson Cancer Center2021-09-21
Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer (NCT04496219)Fred Hutchinson Cancer Center2021-01-22
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma (NCT03513952)National Cancer Institute (NCI)2019-06-05
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer (NCT03237780)National Cancer Institute (NCI)2018-07-20
Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer (NCT02844816)National Cancer Institute (NCI)2017-03-13
Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer (NCT02718742)Mayo Clinic2016-06-01
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer (NCT00749892)M.D. Anderson Cancer Center2008-06-10

Track Recurrent Bladder Urothelial Carcinoma automatically

Every clearance here is in the API, with alerts when new ones post.